The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted priority review for InnoCare Pharma’s orelabrutinib to treat relapsed or refractory marginal zone lymphoma (R/R MZL).

The CDE accepted the supplemental New Drug Application (sNDA) of orelabrutinib for R/R MZL on 12 August this year. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This sNDA is based on findings from an open, multicentre Phase II clinical trial which assessed the safety and efficacy of orelabrutinib to treat R/R MZL.

A highly selective inhibitor of bruton tyrosine kinase (BTK), orelabrutinib is developed by the company to treat autoimmune ailments and cancers.

The therapy obtained conditional approval from the NMPA for two indications in December 2020.

See Also:

Orelabrutinib is indicated to treat R/R chronic lymphocytic leukaemia (CLL) /small lymphocytic lymphoma (SLL) as well as R/R mantle cell lymphoma (MCL). 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Last year, it was included in the National Reimbursement Drug list to benefit several patients with lymphoma.

Currently, multicentre, multi-indication trials of orelabrutinib as a single agent or along with other therapies are progressing in the US and China.

Additionally, it is being analysed in international Phase II trials to treat multiple sclerosis as well as in SLE, primary immune thrombocytopenia and neuromyelitis optica spectrum disorder trials in China.

Orelabrutinib has also received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) to treat r/r MCL.

InnoCare co-founder, chairwoman and CEO Dr Jasmine Cui said: “This is the third indication of orelabrutinib granted priority review. 

“There are unmet medical needs for patients with R/R MZL. We hope orelabrutinib can bring better treatment options to benefit patients with R/R MZL.”